Nurix Therapeutics, Inc.
NRIX
$10.55
$0.313.03%
NASDAQ
| 02/28/2025 | 11/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 38.91% | 5.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 38.91% | 5.53% | |||
| Cost of Revenue | 3.63% | 21.17% | |||
| Gross Profit | 5.06% | -25.75% | |||
| SG&A Expenses | 8.74% | -8.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.33% | 15.99% | |||
| Operating Income | 2.77% | -18.40% | |||
| Income Before Tax | 3.74% | -19.78% | |||
| Income Tax Expenses | -- | -90.24% | |||
| Earnings from Continuing Operations | 3.75% | -19.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.75% | -19.60% | |||
| EBIT | 2.77% | -18.40% | |||
| EBITDA | 4.56% | -21.43% | |||
| EPS Basic | 9.68% | -11.00% | |||
| Normalized Basic EPS | 9.67% | -11.17% | |||
| EPS Diluted | 9.68% | -11.00% | |||
| Normalized Diluted EPS | 9.67% | -11.17% | |||
| Average Basic Shares Outstanding | 6.57% | 7.74% | |||
| Average Diluted Shares Outstanding | 6.57% | 7.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||